# Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

> **NCT00451217** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 198 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT00451217
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-17
- **Primary completion:** 2006-03-06
- **Final completion:** 2006-03-06
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2019-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451217, "Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00451217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*